1 week Ago By Defense World Staff
Corebridge Financial Inc. lessened its holdings in shares of Anavex Life Sciences Corp. ( NASDAQ:AVXL – Free Report ) by 7.
0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,306 shares of the biotechnology company’s stock after selling 2,815 shares during the quarter. Corebridge Financial Inc.
’s holdings in Anavex Life Sciences were worth $401,000 as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other hedge funds have also recently modified their holdings of AVXL. JPMorgan Chase & Co.
lifted its position in Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co.
now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 1,191 shares in the last quarter. China Universal Asset Management Co. Ltd.
lifted its position in shares of Anavex Life Sciences by 10.2% during the 4th quarter. China Universal Asset Management Co.
Ltd. now owns 17,980 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 1,671 shares in the last quarter. Foster Victor Wealth Advisors LLC grew its stake in shares of Anavex Life Sciences by 5.
6% during the 4th quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock valued at $405,000 after acquiring an additional 2,000 shares during the period. Opus Capital Group LLC increased its holdings in Anavex Life Sciences by 6.
1% in the 4th quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company’s stock worth $373,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Nwam LLC raised its stake in Anavex Life Sciences by 0.
3% during the 4th quarter. Nwam LLC now owns 913,051 shares of the biotechnology company’s stock worth $9,806,000 after acquiring an additional 2,575 shares during the period. Institutional investors own 31.
55% of the company’s stock. Analyst Ratings Changes A number of brokerages have recently issued reports on AVXL. D.
Boral Capital reissued a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $42.
00 target price on shares of Anavex Life Sciences in a research report on Monday. Anavex Life Sciences Stock Performance AVXL opened at $8.72 on Thursday.
Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.
44. The company has a fifty day moving average of $8.70 and a 200 day moving average of $8.
48. The stock has a market capitalization of $741.76 million, a price-to-earnings ratio of -15.
85 and a beta of 0.80. Anavex Life Sciences ( NASDAQ:AVXL – Get Free Report ) last issued its quarterly earnings data on Wednesday, February 12th.
The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.
03. On average, equities research analysts forecast that Anavex Life Sciences Corp. will post -0.
69 earnings per share for the current year. Anavex Life Sciences Profile ( Free Report ) Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases.
Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. Featured Stories Five stocks we like better than Anavex Life Sciences Canadian Penny Stocks: Can They Make You Rich? Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore Trading Halts Explained Are Tariffs Threatening Disney’s Comeback Story? Using the MarketBeat Dividend Yield Calculator Is Alphabet a Generational Buying Opportunity at These Levels? Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
